CorDynamics and Elixir Pharmaceuticals Will Present at the Drug Safety Strategies to De-Risk Compounds IBC Life Sciences Conference in August

Chicago, IL (July 2009) - Dr. Michael Gralinski, CorDynamics CEO, and Dr. Rory Curtis, Director of Research for Elixir Pharmaceuticals, have been invited to present at the Drug Safety Strategies to De-Risk Compounds Conference on August 5th and 6th in Boston. The discussion is slated to be part of the IBC Life Sciences Drug Discovery & Development Week.

Drs. Curtis and Gralinski will speak on a strategic testing funnel they designed to screen off-target cardiovascular liabilities from one of the discovery and development platforms implemented at Elixir Pharmaceuticals.

"We are honored to lead a discussion on an increasingly important area of early cardiovascular screening, namely mechanisms not related to QT/QTc interval prolongation," says Dr. Gralinski.

In addition, the relationship between the two organizations will provide a practical illustration of successful scientific collaboration when coupled with R&D outsourcing.

To schedule a consultation with Dr. Gralinski or to garner more information on this upcoming presentation, please contact us at .

Contact:
Michael R. Gralinski, Ph.D., CorDynamics CEO